Avendus Advises Pharmeasy on Series C Funding of USD 50 mn

This round of funding reflects the confidence the investors have in us and in our ability to change the face of healthcare in the country. This infusion will be utilized to build upon a larger consumer base and work towards improving our technology base and put the company on a
rapid growth trajectory without compromising on the superlative consumer experience that we have been known for always. The way we have grown in the last three years, more than 200% YOY is testament to the fact  that affordable and accessible healthcare is very much possible.

It has always been our aim to make healthcare affordable and accessible to everyone. And the new funding will only push us closer to achieving this goal, helping us change the healthcare ecosystem in the country. We plan to use this fund raise to strengthen our tech capabilities in
operations and also in ensuring that we are able to provide personalized healthcare solutions to the consumers. We are so excited that we are enabling this industry with technological interventions which has never happened in the past.

The startup is also working on industry wide issues which revolve around eliminating fake medicines from the system by scrupulously validating prescriptions and barcoding every drug in its inventory to establish their genuineness. Currently, the company is delivering medicines across every single pin code in the country, bringing affordable and authentic healthcare solutions to more than 22000 pin codes. 

PharmEasy is leading the charge in digital disruption in the Indian healthcare ecosystem. The team has demonstrated exceptional executional capabilities backed by deep understanding of the pharmaceutical supply chain and leverages cutting edge technology to provide unparalleled customer experience. With backing from Fundamentum, Eight Roads and Think Investments, PharmEasy is on the path to break into the next orbit and create significant value for all the stakeholders.